<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02186483</url>
  </required_header>
  <id_info>
    <org_study_id>JLP_1310-P1-DI</org_study_id>
    <nct_id>NCT02186483</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin</brief_title>
  <official_title>An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Drug-drug Interaction Following Coadministration of Metformin and Rosuvastatin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetic drug interaction between
      Metformin and Rosuvastatin in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-drug Interaction Following Co-administration of Metformin and Rosuvastatin in Healthy
      Male Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss, AUCÏ„</measure>
    <time_frame>32h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>32h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>32h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>32h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/Fss</measure>
    <time_frame>32h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/Fss</measure>
    <time_frame>32h</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co-administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin,1000mg, once daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_label>Co-administration</arm_group_label>
    <other_name>Glucodown OR SR tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin, 20 mg, once daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_label>Co-administration</arm_group_label>
    <other_name>Crestor tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Rosuvastatin</intervention_name>
    <description>Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_label>Co-administration</arm_group_label>
    <other_name>Glucodown OR SR tablet and Crestor tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~55 years healthy male

          -  BMI measurement 19.0kg/m^2~ 28.0kg/m^2

          -  Signed informed consent form from to participate voluntarily and to comply with the
             trial requirements.

        Exclusion Criteria:

          -  History of clinically significant kidney, liver, gastro-intestinal system,
             cardiovascular system, respiratory system, tumor or blood disorders, nervous system,
             immune system, endocrine disorders, cardiovascular diseases, mental disorders (mood
             disorders, obsessive-compulsive disorder, etc.)

          -  SBP&gt;140mmHg or &lt;90mmHg, DBP&gt;90mmHg or &lt;60mmHg.

          -  An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.

          -  History of drug abuse

          -  A alcohol consumer(alcohol&gt;140g/week) or smoker(cigarette&gt;10 cigarettes/day)
             Hypersensitivity reaction in history of investigational drugs or specific
             drugs(aspirin, antibiotics)

          -  Administrated investigational product in a previous clinical trial within 60 days of
             the screening day in this study.

          -  Administrated drugs which can inhibit or induce OCT2, OATP1B1 transporter within 30
             days of the screening day in this study.(ex: proton pump inhibitor, rifampicin)

          -  Glomerular filtration rate&lt;60mL/min

          -  Donated blood within 60 days prior to the screening day or apheresis blood within 30
             days prior to the screening day .
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-ryul Kim, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center(SMC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center(SMC)</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-Gu</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

